Harm Reduction in HIV Primary Care for PLWH Who Use Drugs
Launched by UNIVERSITY OF PITTSBURGH · May 31, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Harm Reduction in HIV Primary Care for PLWH Who Use Drugs," is studying how healthcare providers' attitudes and practices can improve the care of people living with HIV (PLWH) who also use drugs. The goal is to understand how supportive relationships between patients and providers, as well as specific care strategies known as harm reduction, can help reduce the stigma these patients face in healthcare settings. By exploring these relationships, the researchers hope to find ways to enhance HIV care and improve health outcomes for patients who may be at higher risk due to their drug use.
To participate in this study, you need to be at least 18 years old, living with HIV, and have been receiving HIV care at one of the study sites for at least a year. You should also have used illicit substances or prescription drugs for non-medical reasons recently or in your lifetime. The researchers are looking for both patients and healthcare providers from specific clinics who meet these criteria. Participants can expect to contribute to important research that could lead to better healthcare practices and ultimately help reduce health inequalities for individuals living with HIV who use drugs.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Providers' Inclusion Criteria
- • Working at one of our 3 study sites (UPMC HIV/AIDS Program, Positive Health Clinic, or 1917 Clinic) or one of their partner sites offering substance use treatment (Internal Medicine Recovery Engagement Program, Center for Inclusion Health, or UAB's Outpatient-Based Opioid Treatment Clinic) for at least one year
- • Providing service or care to PLWH or people who use drugs at high risk for HIV acquisition
- • Working in one of the following positions: front desk/patient engagement, social worker, nurse, medical assistant, advanced practice provider, or physician
- • Able to verbally consent, read, and speak English
- • 2. Patient Inclusion Criteria
- • Living with HIV
- • Age 18 or older
- • Able to verbally consent, read, and speak English
- • Receiving HIV medical care from one of the study sites for at least one year
- • Lifetime or recent use (past 3 months) of illicit substances (excluding marijuana) or prescription drugs for non-medical reasons in accordance with the NIDA-Modified ASSIST 2.0.
- Exclusion Criteria:
- • -
About University Of Pittsburgh
The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Birmingham, Alabama, United States
Birmingham, Alabama, United States
Patients applied
Trial Officials
Mary Hawk, DrPH
Principal Investigator
University of Pittsburgh
Emma Kay, PhD
Principal Investigator
University of Alabama at Birmingham
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials